Lake Street Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 58.5%

Neg 58.5% Neu 0% Pos 0%

Lake Street analyst Frank Takkinen maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $10 to $8.